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An insect metabolite containing the little known pyrimido[4,5-b][l,4]diazepine ring system has been found to act as an effective mimic of 
tetrahydrobiopterin its ability to modulate the affinity of interleukin 2 (IL-2) for its receptors on human T cells. Semi-empirical molecular orbital 
calculations reveal that while tetrahydrobiopterin has considerable flexibility, the pyrimidodiazepine has rather few conformational options and 
offers a useful model for exploring the nature of the pterin binding site. 
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1. INTRODUCTION 
Tetrahydrobiopterin (Scheme 1 (1)) is well estab- 
lished as the essential co-factor for the hydroxylation of 
the aromatic amino acids, phenylalanine, tyrosine, and 
tryptophan [l], thus playing an essential role in neuro- 
transmitter biosynthesis and phenylalanine degrada- 
tion. It also serves as a cofactor for the cleavage of 
glyceryl ethers [2], and is involved in the formation of 
nitric oxide from L-arginine [3]. Recently, however, it 
was discovered that it is synthesised in cells which lack 
any of these known biological functions, e.g. in hemato- 
poietic progenitor cells [4,5], and activated T cells [6], 
and a new function for it emerged when it was found 
that it can act as a growth regulator for both of these 
cell types [4,7-91. In T cells, the mechanism for this 
regulatory process of tetrahydrobiopterin (1) involves 
an enhanced affinity of the receptor for IL-2. This effect 
was first noticed [lo] in murine cyotoxic T cells, and was 
then observed [l l] in the human T cell line MT-2. In the 
latter case the response was found to have considerable 
structural specificity, and in a study employing ten 
pteridines, (6R)-5,6,7,8-tetrahydrobiopterin (1) was 
alone in causing a significant increase in receptor affin- 
ity for IL-2. Of the other compounds tested, only biop- 
terin had any measurable ffect, and that was slight. In 
this communication we report that an insect metabolite 
(Scheme 1 (2)) containing the little known pyrimido[4,5- 
b][l,4]diazepine ring system can act as an effective 
mimic of tetrahydrobiopterin (1) in enhancing the affin- 
ity of the IL-2 receptor in human T cells. Furthermore, 
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when stable conformers of the two molecules were iden- 
tified and compared using semi empirical molecular or- 
bital calculations, close spatial correspondences be- 
tween the two were revealed, allowing possible infer- 
ences as to the nature of the binding site. 
2. MATERIALS AND METHODS 
(6R)-5,6,7,8-Tetrahydrobiopterin (1) was obtained from Dr. B. 
Schircks, Jona Laboratories, Switzerland. 6-Acetyl-2-amino-7,8dihy- 
dro-9H-pyrimido[4,5-b][1,4]diazepin_4(3H)-one (2), and 6-acetyl-2,4- 
diamino-7,8-dihydro-9Zf-pyrimido[4,5-b][ 1,4 diazepine (3) were syn- 
thesised as previously described by Boyle et al. [12-141. 
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The K,, values shown in Fig. 1 were obtained by Scatchard analysis 
of equilibrium binding of [‘251]interleukin 2 to the MT-2 cells. The 
origin and methods of long term cultivation of the CD4+ T cell line 
MT-2 are described in reference [6]. For equilibrium binding of the 
ligand, cells were suspended in RPM1 1640 plus 1% bovine serum 
albumin, transferred into Remova strip U-form wells (3 x lo5 cells per 
well) and incubated at 4°C for 40 min with serial dilutions of [‘r51]in- 
terleukin 2 as described in reference [1 11. Tetrahydrobiopterin (1) the 
pyrimidodiazepine (2), and the 4-aminopyrimidodiazepine (3) 
(Scheme 1) were added at a concentration of 3 x lo-’ M. Scatchard 
analysis of the equilibrium binding data (triplicate determinations, 5-7 
independent experiments) was performed with the LIGAND com- 
puter program system (1983 revision) together with the operation 
guide (1987 version) kindly provided by Dr. P.I. Munson, (National 
Institute of Child Health and Human Development, Bethesda, MD 
20205). The program allows pooling of multiple experiments and 
provides calculation of confidence intervals. Details of its principles 
are described in reference [15] and outlined in reference [lo]. 
Energy calculations were performed using the PM3 semi-empirical 
molecular orbital method [16] as implemented in the MOPAC com- 
puter programme; running on a Silicon Graphics IRIS 4D25TG work- 
station. Energy minima were located using maximally stringent con- 
vergence criteria (‘precise’ mode). The initial structures were assem- 
bled using the QUANTA molecular modelling package, supplied by 
Molecular Simulations Inc., Waltham, MA. This software was also 
used for visualisation and comparison of structures. The structure 
matching procedure which yielded the configurations as shown in Fig. 
2 was performed as follows. Energy minimisation of pyrimidodiazep- 
ine (2) yielded conformers in which the O=C-C-CH2 dihedral angle, 
6. took values of -62.4” and +59.7” (AH,= -38.664 and -38.329 
kcal mall’ , respectively). However, the minima were found 
to be shallow with respect to variation of 8, distortions of ? 20” 
requiring 5 0.3 kcal .mol-‘. In attempting to match these conforma- 
tions of (2) to tetrahydrobiopterin (1) it was immediately apparent hat 
the side- chain of the latter must be disposed pseudo-equatonally. 
Candidate structures for tetrahydrobiopterin (1) were generated by 
systematic rotations about the side chain C-C bonds, visual compari- 
son with (2) (bearing in mind the range of angles available to B), and 
energy minimisation in promising cases. In only one case was a close 
correspondence found both between the overall dispositions of the 
side- chains, and between the positions of the carbonyl oxygen in (2) 
and one of the hydroxyl oxygens in (1). This conformational minimum 
for tetrahydrobiopterin (1) was selected and is shown in Fig. 2a. The 
corresponding conformation for pyrimidodiazepine (2), shown in Fig. 
2b, was generated by least squares matching of the asterisked atoms, 
allowing variation of 8. The RMS difference for the positions of the 
superposed atoms was < 0.2 A. 
3. RESULTS AND DISCUSSION 
An integral part of the cellular immune response 
mechanism is the clonal expansion of T cells induced by 
the binding of interleukin 2 (IL-2) to specific high affin- 
ity receptors [17-191. It was discovered recently that 
(6R)-tetrahydrobiopterin, which is produced by the T 
cells [6], modulates the affinity of these receptors for 
IL-2 [lo], and this constitutes a feedback mechanism 
resulting in an enhanced entry of the T cells into the 
DNA synthesis phase. As already mentioned, several 
pteridines closely related to tetrahydrobiopterin failed 
to give a similar effect [l 11. The present experiments 
show, however, that the pyrimidodiazepine (2), which 
occurs naturally as an insect metabolite, is almost as 
effective as tetrahydrobiopterin (1) in its ability to pro- 
mote the affinity of the receptors for IL-2. 
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The insect metabolite (2) used in this work was first 
isolated [20] in 1977 from the heads of Drosophila 
melanogaster. It is biosynthetically related to tetrahy- 
drobiopterin (1) in that the two molecules hare a com- 
mon precursor [21]. However, it is structurally rather 
different [22,23] and is, in effect, a ‘homopteridine’. 
Heretofore its only known biological significance 
[21,24] has been as an intermediate on the biogenetic 
pathway to the drosopterins, the red eye pigments of the 
insect. Until recently any further investigations of its 
properties were hampered by lack of material, but its 
chemical synthesis [12] has made available sufficient 
quantities for the present experiments. Its 4-amino ana- 
logue (3) was also synthesised [13,14] and tested, since 
it is well known that some of the most effective folic acid 
antagonists are those in which the pterin 4-0~0 group 
has been replaced by a 4-amino group. In our experi- 
ments, we used the HTLV-I infected CD4’ T cell line 
MT-2, firstly because it expresses both chains of the 
IL-2 high affinity receptor [ 18,251 and secondly, because 
it lacks constitutive tetrahydrobiopterin synthesis [6]. 
The apparent affinity of the IL-2 receptor was measured 
by determining the Kd values of [“‘I]IL-2, and the re- 
sults are shown in Fig. 1. As can be seen, the Kd value 
of the control MT-2 cells decreased by about half when 
either tetrahydrobiopterin (1) or the insect metabolite 
(2) was added. In other words, the affinity of the recep- 
tor for IL-2 was about doubled in presence of either of 
these compounds. The amino analogue (3) had no ef- 
fect. 
The cellular immune response depends upon proper 
control of T cell amplification. It is initiated by IL-2 
binding to its high affinity receptor complex which is 
composed of the a, j?, and y subunits [18,19,26]. Recent 
evidence supports a more complex structure that in- 
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Fig. 1. Modulation of the interleukin 2 receptor affinity of MT-2 cells 
for the ligand. Tetrahydrobiopterin, (6R)-5,6,7,8-tetrahydrobiopterin 
(1); pyrimidodiazepine, 6-acetyl-2-amino-7,8-dihydro-9H-pynm- 
ido[4,5-b][l,4]diazepin-4(3H)-one (2); 4-aminopyrimidodiazepine, 6- 
acetyl-2,4-diamino-7,8-dihydro-9H-pyrimido[4,5-b][1,4]diazepine (3). 
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Fig. 2. Hypothetical active conformations of tetrahydrobiopterin (1) 
and pyrimidodiazepine (2), shown separately in (a) and (b) respec- 
tively, and superimposed in (c). 
volves additional proteins such as the intercellular adhe- 
sion molecule-l (ICAM-1) or the class I HLA molecule 
[19]. Available evidence suggests that the binding sites 
for tetrahydrobiopterin (l), and presumably also for 
pyrimidodiazepine (2), are located on the class I HLA 
molecules [27]. In an earlier study [l 11, semi-empirical 
molecular orbital (SMO) calculations on tetrahydro- 
biopterin (1) showed that while the bicyclic pteridine 
nucleus is structurally well-defined, the side chain at 
position 6 can occupy pseudoaxial or pseudoequatorial 
orientations. The side chain is also quite flexible, such 
that the molecule has at least eight energy minima 
within 1.5 kcal/mol of baseline. (Other recent calcula- 
tions [28] may not have revealed the global minimum 
energy conformation, since a limited number of starting 
points was used.) Because of the flexibility of the side 
chain, any inferences which can be drawn from the cal- 
culations concerning the binding site of tetrahydrobiop- 
terin (1) are limited. On the other hand, the pyrimidodi- 
azepine (2) has less conformational freedom than (1) 
and, superficially at least, a quite different structure. It 
might be expected that a survey of its conformational 
space would reveal only a few points of intersection with 
(1) thus providing clear guidance as to the receptor 
structure. Indeed, a process of structure matching using 
configurations generated by SMO theory revealed very 
few pairs of conformations which showed reasonable 
correspondence. There was one pair which seemed out- 
standing, however, as illustrated in (a) and (b) in Fig. 
2. Tetrahydrobiopterin (1) in the conformation shown 
in (a) is only 0.23 kcal.mol-’ above its global minimum 
as located in our earlier study [l I]. Pyrimidodiazepine 
(2) in the conformation shown in (b) has 0 = 70.8”, and 
is thus very close to one of its energy minima. After 
superposition of the atoms marked with asterisks in the 
pyrimidine nuclei, the two side-chains were found to 
occupy much the same region of space, and the acetyl 
oxygen in the pyrimidodiazepine was found to lie within 
0.22 A of the Cl’ oxygen in tetrahydrobiopterin. This 
is illustrated in (c), which shows conformations (a) and 
(b), of (1) and (2) respectively, superposed. Both con- 
formations (a) and (b) are among the lowest-energy 
conformations of their respective molecules, and the 
conclusion that the compounds are bound to the recep- 
tor in these forms is, at least, a good working hypothe- 
sis. If correct, it may help direct research towards the 
development of small-molecule immunostimulants with 
therapeutic applications. 
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